855 results on '"Turnidge, John"'
Search Results
2. Estimation of epidemiological cut-off values for eight antibiotics used for treatment of bovine mastitis caused by Streptococcus uberis and Streptococcus dysgalactiae subsp. dysgalactiae
3. Responsible prescribing for URTIs
4. Antimicrobials: Priorities for action
5. Minimising bacterial resistance in general practice
6. Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution
7. Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy
8. How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff values
9. A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens
10. Inactivation, removal, and regrowth potential of opportunistic pathogens and antimicrobial resistance genes in recycled water systems
11. Searching High and Low: Call for a Joint European Society for Paediatric Infectious Diseases-European Committee on Antimicrobial Susceptibility Testing Survey on Dosage of Antibacterial Agents in Children—Part One
12. Polymyxin Susceptibility Testing and Breakpoint Setting
13. The scope of antimicrobial resistance in residential aged care facilities determined through analysis of Escherichia coli and the total wastewater resistome
14. The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series
15. Proposed method for estimating clinical cut-off (COCL) values: An attempt to address challenges encountered when setting clinical breakpoints for veterinary antimicrobial agents
16. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial
17. Determination of disk diffusion susceptibility testing interpretive criteria using model-based analysis: development and implementation
18. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds
19. Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
20. Drug–Drug Combinations
21. Antimicrobial susceptibility testing for bovine respiratory disease: Getting more from diagnostic results
22. 40: ROBOTIC ANTIMICROBIAL SUSCEPTIBILITY PLATFORM FOR SURVEILLANCE OF ANTIMICROBIAL RESISTANCE IN SENTINEL SPECIES
23. Establishment of RCPA national guidelines for selective reporting of antimicrobials: processes, challenges and measuring the impact
24. Quality control ranges for cefoperazone 30 μg disks for Staphylococcus aureus ATCC® 25923 and Escherichia coli ATCC® 25922
25. The Urgent Need for Clear and Accurate Information on the Polymyxins
26. Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia
27. Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing
28. Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials
29. Searching high and low: call for a joint ESPID-EUCAST survey on dosage of antibacterial agents in children–part one
30. Reply to Gould
31. EUCAST breakpoint categories and the revised “I”: a stewardship opportunity for “I”mproving outcomes
32. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
33. Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations
34. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study
35. Development of Quality Control Ranges for Biocide Susceptibility Testing
36. High Burden of Staphylococcal Disease in Indigenous Communities
37. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective
38. The Wastewater Resistome of Residential Aged Care Facilities Indicates a Role of Antimicrobial Stewardship in Reducing Resistance
39. Worldwide distribution and environmental origin of the Adelaide imipenemase (AIM-1), a potent carbapenemase in Pseudomonas aeruginosa
40. The publication of studies involving the use of human critically important antimicrobial agents in veterinary species: Reply from the authors
41. Susceptibility Test Methods: General Considerations
42. Susceptibility Test Methods: Dilution and Disk Diffusion Methods
43. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection
44. Taking AIM-(1) at carbapenem resistance in Pseudomonas aeruginosa
45. Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers
46. Reviving old antibiotics
47. Response to letter from J Mottet “Comments on the ISCAID Guidelines on the use of antimicrobial therapies in canine superficial bacterial folliculitis”
48. Comparative macrolide use in humans and animals: should macrolides be moved off the World Health Organisation’s critically important antimicrobial list?
49. What Can Be Done about Resistance to Antibiotics?
50. Drug–Drug Combinations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.